PD L1 News and Research

RSS

Ferroptosis could be the key to making effective immunotherapies against liver cancer

Iron-dependent cell death (ferroptosis) is a type of programmed cell death by means of which the body kills off diseased, defective or superfluous cells.

17 Feb 2023

Neoadjuvant nivolumab treatment improves survival rates in NSCLC patients

Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.

15 Feb 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

New therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line

A new research perspective was published in Genes & Cancer on January 30, 2023, entitled, "Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines."

3 Feb 2023

Researchers develop AI-based strategy for discovering high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

30 Jan 2023

Researchers discover mechanism underlying the development and intensification of cancer treatment-related pain

A combination of chemotherapy and drugs that stimulate the immune system to combat cancer is increasingly used to control progression of the disease in patients.

30 Jan 2023

New therapy-relevant marker may help identify ER+ breast cancer patients who may benefit from immunotherapies

A multi-institutional team led by scientists from the Medical College of Wisconsin Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.

26 Jan 2023

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy with or without bevacizumab is possible.

25 Jan 2023

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

Immunotherapy is a way of treating cancer by reprogramming the patient's immune system to attack their tumor.

10 Jan 2023

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS).

28 Dec 2022

Extracellular vesicles enhance cancer immunotherapy

Nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumors sensitive to a type of immunotherapy drug called a checkpoint inhibitor.

22 Dec 2022

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

An experimental therapy showed promise as treatment for an aggressively spreading type of colorectal cancer in preclinical models, according to a new study by Weill Cornell Medicine investigators.

16 Dec 2022

Researchers discover how certain breast cancers persist after chemo and do not respond to immunotherapies

Thanks to advances in cancer therapies, most forms of breast cancer are highly treatable, especially when caught early.

15 Dec 2022

AI could make doctors’ work simpler, faster, and more precise

One in nine women in the developed world will be diagnosed with breast cancer at some point in her life. The prevalence of breast cancer is increasing, an effect caused in part by the modern lifestyle and increased lifespans.

2 Dec 2022

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

28 Oct 2022

Immune checkpoint therapy may be beneficial in certain cases of severe COVID-19

An article published in Science Advances suggests that a type of cancer treatment known as immune checkpoint blockade may be beneficial in certain cases of severe COVID-19.

27 Oct 2022

Researchers circumvent a key mechanism in castration-resistant prostate cancer

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that they can circumvent a key mechanism in castration-resistant prostate cancer (CRPC) and possibly make immunotherapies more effective.

20 Oct 2022

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM).

20 Sep 2022

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.

13 Sep 2022